Conditions of the State Drug Administration to approve the listing

Recently, the State Drug Administration has approved the approval of the first -class type of innovative drugs (product name: Ereyn) reported by Jiangsu Hengrui Pharmaceutical Co., Ltd.The drug is suitable for patients with metastatic hormone -sensitive prostate (MHSPC) patients with high tumor load.

Revilunamide is arogen receptor (AR) inhibitor, which can competitive androgen combination with AR, thereby inhibiting the combination of AR nuclear and DNA, and reducing the gene transcription of AR media.The listing of this variety provides new treatment options for patients with prostate cancer.

- END -